Xiaobin Wu Sells 500 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $200.00, for a total transaction of $100,000.00. Following the sale, the chief operating officer now owns 4,500 shares of the company’s stock, valued at approximately $900,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, September 19th, Xiaobin Wu sold 4,500 shares of BeiGene stock. The shares were sold at an average price of $200.14, for a total transaction of $900,630.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The stock was sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Price Performance

Shares of NASDAQ:BGNE opened at $201.99 on Friday. The firm has a 50 day moving average of $182.24 and a 200-day moving average of $164.48. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $215.00. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $19.57 billion, a PE ratio of -26.68 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($2.27) by $1.12. The business had revenue of $929.20 million during the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company’s revenue was up 56.1% on a year-over-year basis. During the same period in the previous year, the business earned ($3.64) earnings per share. On average, equities research analysts predict that BeiGene, Ltd. will post -5.13 EPS for the current fiscal year.

Institutional Trading of BeiGene

Several institutional investors and hedge funds have recently modified their holdings of the business. Headlands Technologies LLC bought a new position in BeiGene in the first quarter valued at about $50,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of BeiGene by 51.5% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after purchasing an additional 279 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of BeiGene during the 4th quarter valued at approximately $183,000. Acadian Asset Management LLC increased its position in BeiGene by 204.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after purchasing an additional 849 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. bought a new position in BeiGene in the 1st quarter valued at approximately $209,000. 48.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BGNE shares. Bank of America lowered their price objective on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. JMP Securities assumed coverage on shares of BeiGene in a research report on Wednesday. They set a “market outperform” rating and a $288.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Finally, Citigroup raised their target price on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.21.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.